New immune booster FL115 tested in patients with advanced cancers
NCT ID NCT06130722
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a new drug called FL115 in 18 adults with advanced solid tumors that had stopped responding to standard treatments. FL115 is designed to strengthen the body's immune cells to fight cancer. The main goal was to check safety and find the right dose, while also looking for any signs that the drug might shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
FL115 (a lab-made protein that boosts immune cells)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong
This is a very early, small Phase 1 trial with only 18 participants. The main goal is safety, not effectiveness, and many early-stage drugs fail to show benefit in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Gabriel Cancer Center
Canton, Ohio, 44718, United States
-
HOAG Memorial Hospital Presbyterian
Newport Beach, California, 92663, United States
-
Moores Cancer Center at UCSD Health
San Diego, California, 92037, United States